Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Immutep Ltd ( (AU:IMM) ).
Immutep Ltd announced a change in the director’s interest, specifically involving Dr. Russell John Howard. The changes include the acquisition and conversion of performance rights into ordinary shares, as approved by shareholders at recent annual general meetings. This adjustment reflects Dr. Howard’s decision to take a portion of his fees in performance rights, aligning his interests with the company’s long-term growth and shareholder value.
The most recent analyst rating on (AU:IMM) stock is a Hold with a A$0.28 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
More about Immutep Ltd
Immutep Ltd is a biotechnology company focused on developing immunotherapy treatments for cancer and autoimmune diseases. The company’s primary products include a range of therapeutic antibodies and related technologies, with a market focus on enhancing the body’s immune response to fight diseases.
Average Trading Volume: 2,329,094
Technical Sentiment Signal: Sell
Current Market Cap: A$375.3M
For detailed information about IMM stock, go to TipRanks’ Stock Analysis page.